Donor and transplant characteristics
| . | Secondary MDS/tAML, no. (%) . | De novo MDS/tAML, no. (%) . |
|---|---|---|
| n | 257 | 339 |
| Donor type | ||
| Related | ||
| HLA-genotypically identical sibling | 108 (42) | 145 (43) |
| HLA-nonidentical family member* | 25 (10) | 20 (6) |
| Syngeneic twin | 2 (1) | 4 (1) |
| Unrelated | ||
| HLA-identical | 98 (38) | 98 (29) |
| HLA-nonidentical* | 24 (9) | 72 (21) |
| Source of stem cells | ||
| Marrow | 150 (58) | 177 (52) |
| PBPCs | 102 (40) | 162 (48) |
| Cord blood | 5 (2) | — |
| Transplant conditioning regimen | ||
| BUCY/tBUCY | 29 (11)/93 (36) | 13 (4)/172 (51) |
| High-dose TBI | 83 (32) | 122 (36) |
| FLutBU | 12 (5) | 22 (6) |
| FluTBI (200) | 26 (10) | — |
| Miscellaneous chemotherapy regimens† | 14 (5) | 10 (3) |
| Interval from diagnosis to HCT, mo | ||
| 0 to 6 | 148 (58) | 138 (41) |
| 7 to 12 | 60 (23) | 95 (28) |
| 13 to 24 | 29 (11) | 58 (17) |
| Longer than 24 | 20 (%) | 48 (14) |
| Year of transplantation | ||
| 2000 to 2006 | 116 (45) | 147 (43) |
| 1990 to 1999 | 121 (47) | 192 (57) |
| 1980 to 1989 | 20 (8) | 0 |
| . | Secondary MDS/tAML, no. (%) . | De novo MDS/tAML, no. (%) . |
|---|---|---|
| n | 257 | 339 |
| Donor type | ||
| Related | ||
| HLA-genotypically identical sibling | 108 (42) | 145 (43) |
| HLA-nonidentical family member* | 25 (10) | 20 (6) |
| Syngeneic twin | 2 (1) | 4 (1) |
| Unrelated | ||
| HLA-identical | 98 (38) | 98 (29) |
| HLA-nonidentical* | 24 (9) | 72 (21) |
| Source of stem cells | ||
| Marrow | 150 (58) | 177 (52) |
| PBPCs | 102 (40) | 162 (48) |
| Cord blood | 5 (2) | — |
| Transplant conditioning regimen | ||
| BUCY/tBUCY | 29 (11)/93 (36) | 13 (4)/172 (51) |
| High-dose TBI | 83 (32) | 122 (36) |
| FLutBU | 12 (5) | 22 (6) |
| FluTBI (200) | 26 (10) | — |
| Miscellaneous chemotherapy regimens† | 14 (5) | 10 (3) |
| Interval from diagnosis to HCT, mo | ||
| 0 to 6 | 148 (58) | 138 (41) |
| 7 to 12 | 60 (23) | 95 (28) |
| 13 to 24 | 29 (11) | 58 (17) |
| Longer than 24 | 20 (%) | 48 (14) |
| Year of transplantation | ||
| 2000 to 2006 | 116 (45) | 147 (43) |
| 1990 to 1999 | 121 (47) | 192 (57) |
| 1980 to 1989 | 20 (8) | 0 |
HLA indicates human leukocyte antigen; PBPCs, peripheral blood progenitor cells; BU, busulfan; tBU, targeted BU; CY, cyclophosphamide; TBI, total-body irradiation (high-dose = 920-1575 cGy); Flu, fludarabine; ATG, antithymocyte globulin; L-pam, phenylalanine mustard; Pred, prednisolone; Treo, treosulfan; VP-16, etoposide; and —, not applicable.
Differing at the allele or antigen level for one or two HLA loci.
Flu/CY/TBI/ATG, BU/L-pam/Pred/ATG; Flu/Treo; or Flu/VP-16.